Retts:
in 2015 they attribute a probability adjusted NPV for retts of $149 mill and now in 2017 we have have a phase 2b success and almost ready to get P3 ticked off and a NPV increase of just 11 mill ($160 mil!).
Lilypily, as you say, Bell Potter has attributed a probability adjusted NPV of $160 million for trofinetide in Rett Syndrome.
I note that a further valuation report was put out for (Swiss) Newron Pharmaceuticals last month. Newron has been mentioned on this forum before. To refresh, its drug, sarizotan, is being developed for respiratory symptoms in Rett Syndrome. By Newron’s estimates, roughly 50% of Rett patients have such breathing disturbances. Newron is currently running a single “potentially pivotal” Phase 2/3 clinical trial. Sarizotan’s efficacy in this condition has only been previously demonstrated in mice. The clinical trial site says that the current trial is expected to complete in December 2018.
The report analyst has estimated an NPV for sarizotan in Rett syndrome equivalent to AU$338 million. That’s using a success probability of 25%.
Yes, that’s more than double the probability adjusted NPV that Bell Potter has estimated for trofinetide in Rett Syndrome. What’s more, that’s for a drug which addresses just one symptom of Rett, in just 50% of the Rett market.
Go figure…
https://www.valuationlab.com/research-coverage/research/
https://clinicaltrials.gov/ct2/show/NCT02790034?term=rett syndrome&rank=13
- Forums
- ASX - By Stock
- NEU
- bell potter
bell potter, page-15
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.01 |
Change
-0.010(0.08%) |
Mkt cap ! $1.662B |
Open | High | Low | Value | Volume |
$13.06 | $13.26 | $12.81 | $5.865M | 451.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 14541 | $13.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.02 | 2438 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 14541 | 13.000 |
1 | 75 | 12.990 |
1 | 2500 | 12.960 |
1 | 300 | 12.950 |
4 | 3866 | 12.940 |
Price($) | Vol. | No. |
---|---|---|
13.020 | 2438 | 1 |
13.030 | 867 | 1 |
13.040 | 69 | 1 |
13.050 | 3366 | 3 |
13.070 | 1999 | 1 |
Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online